ARCT
Price
$19.48
Change
+$0.25 (+1.30%)
Updated
Aug 15 closing price
Capitalization
528.97M
81 days until earnings call
CORT
Price
$71.75
Change
-$0.25 (-0.35%)
Updated
Aug 15 closing price
Capitalization
7.56B
74 days until earnings call
Interact to see
Advertisement

ARCT vs CORT

Header iconARCT vs CORT Comparison
Open Charts ARCT vs CORTBanner chart's image
Arcturus Therapeutics Holdings
Price$19.48
Change+$0.25 (+1.30%)
Volume$994.18K
Capitalization528.97M
Corcept Therapeutics
Price$71.75
Change-$0.25 (-0.35%)
Volume$692.63K
Capitalization7.56B
ARCT vs CORT Comparison Chart in %
Loading...
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CORT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARCT vs. CORT commentary
Aug 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARCT is a Hold and CORT is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 16, 2025
Stock price -- (ARCT: $19.48 vs. CORT: $71.75)
Brand notoriety: ARCT and CORT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARCT: 173% vs. CORT: 59%
Market capitalization -- ARCT: $528.97M vs. CORT: $7.56B
ARCT [@Biotechnology] is valued at $528.97M. CORT’s [@Biotechnology] market capitalization is $7.56B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.71B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARCT’s FA Score shows that 0 FA rating(s) are green whileCORT’s FA Score has 1 green FA rating(s).

  • ARCT’s FA Score: 0 green, 5 red.
  • CORT’s FA Score: 1 green, 4 red.
According to our system of comparison, CORT is a better buy in the long-term than ARCT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARCT’s TA Score shows that 6 TA indicator(s) are bullish while CORT’s TA Score has 5 bullish TA indicator(s).

  • ARCT’s TA Score: 6 bullish, 4 bearish.
  • CORT’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, CORT is a better buy in the short-term than ARCT.

Price Growth

ARCT (@Biotechnology) experienced а +63.56% price change this week, while CORT (@Biotechnology) price change was -0.77% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.90%. For the same industry, the average monthly price growth was +26.70%, and the average quarterly price growth was +20.91%.

Reported Earning Dates

ARCT is expected to report earnings on Nov 05, 2025.

CORT is expected to report earnings on Oct 29, 2025.

Industries' Descriptions

@Biotechnology (+9.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CORT($7.56B) has a higher market cap than ARCT($529M). CORT YTD gains are higher at: 42.379 vs. ARCT (14.791). CORT has higher annual earnings (EBITDA): 104M vs. ARCT (-63.92M). CORT has more cash in the bank: 342M vs. ARCT (217M). CORT has less debt than ARCT: CORT (6.61M) vs ARCT (42.7M). CORT has higher revenues than ARCT: CORT (716M) vs ARCT (131M).
ARCTCORTARCT / CORT
Capitalization529M7.56B7%
EBITDA-63.92M104M-61%
Gain YTD14.79142.37935%
P/E RatioN/A64.06-
Revenue131M716M18%
Total Cash217M342M63%
Total Debt42.7M6.61M646%
FUNDAMENTALS RATINGS
ARCT vs CORT: Fundamental Ratings
ARCT
CORT
OUTLOOK RATING
1..100
8388
VALUATION
overvalued / fair valued / undervalued
1..100
46
Fair valued
82
Overvalued
PROFIT vs RISK RATING
1..100
10042
SMR RATING
1..100
9542
PRICE GROWTH RATING
1..100
3845
P/E GROWTH RATING
1..100
1009
SEASONALITY SCORE
1..100
4785

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARCT's Valuation (46) in the Pharmaceuticals Major industry is somewhat better than the same rating for CORT (82) in the Pharmaceuticals Other industry. This means that ARCT’s stock grew somewhat faster than CORT’s over the last 12 months.

CORT's Profit vs Risk Rating (42) in the Pharmaceuticals Other industry is somewhat better than the same rating for ARCT (100) in the Pharmaceuticals Major industry. This means that CORT’s stock grew somewhat faster than ARCT’s over the last 12 months.

CORT's SMR Rating (42) in the Pharmaceuticals Other industry is somewhat better than the same rating for ARCT (95) in the Pharmaceuticals Major industry. This means that CORT’s stock grew somewhat faster than ARCT’s over the last 12 months.

ARCT's Price Growth Rating (38) in the Pharmaceuticals Major industry is in the same range as CORT (45) in the Pharmaceuticals Other industry. This means that ARCT’s stock grew similarly to CORT’s over the last 12 months.

CORT's P/E Growth Rating (9) in the Pharmaceuticals Other industry is significantly better than the same rating for ARCT (100) in the Pharmaceuticals Major industry. This means that CORT’s stock grew significantly faster than ARCT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARCTCORT
RSI
ODDS (%)
Bearish Trend 1 day ago
85%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
70%
Momentum
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
75%
MACD
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
71%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 1 day ago
66%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
63%
Advances
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 9 days ago
81%
Declines
ODDS (%)
Bearish Trend 6 days ago
87%
Bearish Trend 1 day ago
65%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
Aroon
ODDS (%)
Bullish Trend 1 day ago
85%
Bearish Trend 1 day ago
40%
View a ticker or compare two or three
Interact to see
Advertisement
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CORT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYPIX62.84N/A
N/A
Rydex Transportation Inv
FDEIX28.22N/A
N/A
Fidelity Advisor Capital Development I
HEMZX7.77N/A
N/A
Virtus SGA Emerging Markets Equity A
BNIEX12.07N/A
N/A
UBS International Sustainable Equity A
SXPCX52.55N/A
N/A
DWS S&P 500 Index C

ARCT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARCT has been loosely correlated with CLDX. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if ARCT jumps, then CLDX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARCT
1D Price
Change %
ARCT100%
+1.30%
CLDX - ARCT
51%
Loosely correlated
+2.25%
RGNX - ARCT
51%
Loosely correlated
-2.65%
RXRX - ARCT
51%
Loosely correlated
+2.30%
BEAM - ARCT
51%
Loosely correlated
+1.08%
PDSB - ARCT
49%
Loosely correlated
-0.83%
More

CORT and

Correlation & Price change

A.I.dvisor indicates that over the last year, CORT has been loosely correlated with TENX. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if CORT jumps, then TENX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CORT
1D Price
Change %
CORT100%
-0.35%
TENX - CORT
41%
Loosely correlated
+0.34%
AGIO - CORT
41%
Loosely correlated
+0.90%
DNLI - CORT
40%
Loosely correlated
+1.66%
ARCT - CORT
37%
Loosely correlated
+1.30%
INSM - CORT
37%
Loosely correlated
+0.04%
More